Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
marstacimab · 2 trials · 3 indications
Derived for each subject for each period (historical and study treatment) by using the following formula: ABR = number of bleeds requiring treatments/ (days on treatment period / 365.25)
| Arm | Type | Description |
|---|---|---|
| marstacimab (PF-06741086) | EXPERIMENTAL | Weekly subcutaneous injections. |
| MARSTACIMAB | EXPERIMENTAL | Marstacimab 150 mg subcutaneous (SC) once weekly (QW) |
| Name | Type | Description |
|---|---|---|
| marstacimab | DRUG | marstacimab |
Inclusion Criteria: * Male participants of appropriate age and required minimum weight * Participants aged 12 to 17 years must be at least 25 kgs at time of consent. * Participants aged 6 to 11 years must be at least 19 kgs at time of consent. * Minimum weight requirement for participants aged 1 to...
Marstacimab is an investigational antibody being developed for hemophilia A, including severe hemophilia A. It is being studied in clinical trials for patients with hemophilia A and hemophilia B, with a focus on pediatric and adult populations. The drug is currently in clinical development and has not been approved by regulatory authorities.
Marstacimab is a monoclonal antibody, indicated by its -mab suffix. It is being studied for its role in treating hemophilia A and B. The specific molecular target of Marstacimab has not been disclosed in the available information, but as an antibody, it is designed to interact with specific proteins involved in blood clotting.
Marstacimab is being developed by Pfizer, Inc., a global pharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. Pfizer is conducting clinical trials to evaluate the safety and efficacy of Marstacimab in patients with hemophilia A and B.
Marstacimab is in Phase 1 clinical development. While one trial listed under the drug is a Phase 3 study, the most advanced stage of development for Marstacimab itself is Phase 1, as indicated by the drug's overall phase designation. It remains an investigational agent and is not yet approved.
Marstacimab is being studied in two clinical trials. NCT05611801 is a Phase 3 trial in pediatric patients with hemophilia A or B, enrolling 100 participants across multiple countries. NCT06703606 is a Phase 1 trial studying the switch from emicizumab to Marstacimab in patients with severe hemophilia A, enrolling 15 participants.
No, Marstacimab is not the same as emicizumab. They are different drugs. One clinical trial, NCT06703606, is specifically studying what happens when patients switch from emicizumab to Marstacimab, indicating they are distinct therapies with potentially different mechanisms of action.